


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A compound of formula I



in which

$R^2$ ,  $R^4$  denote H, A, Hal, cycloalkyl having 3 to 7 C atoms,  $CF_3$ ,  $NO_2$ , CN,  $OCF_3$ , OA, NHA,  $NA_2$ , or  $NH_2$ ,

$R^6$  is phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl,

$R^3$  is phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl or 2- or 3-furanyl,


$R^1$  denotes H or  $CO_2R^5$ ,  $(CH_2)_nCOHet$ , CHO,  $(CH_2)_nOR^5$ ,  $(CH_2)_nHet$ ,  $(CH_2)_nN(R^5)_2$ ,  $CH=N-OA$ ,  $CH_2CH=N-OA$ ,  $(CH_2)_nNHOA$ ,  $(CH_2)_n(R^5)Het$ ,  $(CH_2)_nCH=N-Het$ ,  $(CH_2)_nOCOR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2OR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2OCF_3$ ,















$(\text{CH}_2)_n\text{N}(\text{R}^5)\text{C}(\text{R}^5)\text{OCOR}^5$ ,  $(\text{CH}_2)_n\text{N}(\text{R}')\text{CH}_2\text{COHet}$ ,  $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{Het}$ ,  
 $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{Het}$ ,  $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{N}(\text{R}')\text{CH}_2\text{OCOR}^5$ ,  
 $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{N}(\text{R}^5)_2$ ,  $\text{CH}=\text{CHCOOR}^5$ ,  $\text{CH}=\text{CHCH}_2\text{NR}^5\text{Het}$ ,  $\text{CH}=\text{CHCH}_2\text{N}(\text{R}^5)_2$ ,  
 $\text{CH}=\text{CHCH}_2\text{OR}^5$  or  $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{Ar}$ ,

















$\text{R}^5$  denotes H or A















A denotes straight-chain or branched alkyl or alkoxy having 1 to 10 C atoms, or alkenyl or alkenyloxyalkyl having 2 to 10 C atoms,


Het is 1-piperidyl, 1-piperazyl, 1-(4-methyl)piperazyl, 1-(4-ethyl)piperazinyl, 1-(4-cyclopentyl)piperazinyl, 4-methylpiperazin-1-ylamine, 1-pyrrolidinyl, 1-pyrazolidinyl, 1-(2-methyl)pyrazolidinyl, 1-imidazolidinyl or 1-(3-methyl)imidazolidinyl or 4-pyridyl, which is unsubstituted or substituted by one or more CN group, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl, or a group of one of the formulae below





Ar denotes a phenyl radical which is unsubstituted or mono or polysubstituted by A and/or Hal, OR<sup>5</sup>, OOCR<sup>5</sup>, COOR<sup>5</sup>, CON(R<sup>5</sup>)<sub>2</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, NHCOR<sup>5</sup>, CF<sub>3</sub> or SO<sub>2</sub>CH<sub>3</sub>,

X denotes CH or N,

n denotes 0, 1, 2, 3, 4 or 5 and

Hal denotes F, Cl, Br or I,




where, in the case that X has the meaning CH, R<sup>2</sup> and R<sup>4</sup> do not simultaneously denote H,

or a salt, enantiomer, or racemate thereof, or a mixture of enantiomers.




2. (Cancelled)

3. (Currently Amended) A compound according to claim 28 [[+]], in which R<sup>4</sup> denotes H, Hal, CN, A or NO<sub>2</sub>.

4. (Currently Amended) A compound according to claim 28 [[+]], in which R<sup>2</sup> denotes H or alkyl.
5. (Cancelled)
6. (Previously Presented) A compound according to claim 1, in which X has the meaning N.
7. (Currently Amended) A compound of formula IA, IB, IC, ID, IE or IF:







in which

R<sup>3</sup> is phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl or 2- or 3-furanyl,

R<sup>4</sup> denote H, A, Hal, cycloalkyl having 3 to 7 C atoms, CF<sub>3</sub>, NO<sub>2</sub>, CN, OCF<sub>3</sub>, OA, NHA, NA<sub>2</sub>, or NH<sub>2</sub>,

A denotes straight-chain or branched alkyl or alkoxy having 1 to 10 C atoms, or alkenyl or alkenyloxyalkyl having 2 to 10 C atoms,

Hal denotes F, Cl, Br or I,


X denotes CH or N,

where, in the case that X has the meaning CH, R<sup>4</sup> in the compounds of formulae IA, IC and IE does not denote H, and

R<sup>6</sup> is phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl


**R<sup>3</sup>, R<sup>4</sup>, R<sup>6</sup> and X have the meanings indicated for the compound of formula I.**

8. (Previously Presented) A process for preparing a compound of claim 1, which is of formula IA



in which R<sup>3</sup>, R<sup>4</sup>, R<sup>6</sup>, X and A have the meaning indicated for the compound of formula I or a salt thereof,

comprising reacting a compound of formula II




or an acid-addition salt thereof,

in which  $R^4$ ,  $R^6$  and X have the meanings indicated for the compound of formula I,  
with a compound of formula III



in which A and  $R^3$  have the meanings indicated for the compound of formula I,  
and/or converting a basic compound of formula IA into one of its salts by treatment with an acid.

9. (Currently Amended) A process for preparing a compound of claim 1, which is of formula IB



in which

$R^3$  is phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-,

n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl or 2- or 3-furanyl,

R<sup>4</sup> denote H, A, Hal, cycloalkyl having 3 to 7 C atoms, CF<sub>3</sub>, NO<sub>2</sub>, CN, OCF<sub>3</sub>, OA, NHA, NA<sub>2</sub>, or NH<sub>2</sub>,


A denotes straight-chain or branched alkyl or alkoxy having 1 to 10 C atoms, or alkenyl or alkenyloxyalkyl having 2 to 10 C atoms,

Hal denotes F, Cl, Br or I,

X denotes CH or N,

R<sup>6</sup> is phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl,


~~R<sup>3</sup>, R<sup>4</sup>, R<sup>6</sup>, X and A have the meaning indicated for the compound of formula I~~  
or a salt thereof,  
comprising reacting a compound of formula II



or an acid-addition salt thereof,

in which R<sup>4</sup>, R<sup>6</sup> and X have the meanings indicated for the compound of ~~formula IB~~ formula I,


with a compound of formula IV



in which A and  $\text{R}^3$  have the meanings indicated for the compound of ~~formula IB~~ formula I, and/or converting a basic compound of formula IB into one of its salts by treatment with an acid.

10-13. (Cancelled)

14. (Currently Amended) A pharmaceutical composition comprising at least one compound of the formula I ~~according to claim 1~~ and/or one of its physiologically acceptable salts, and a pharmaceutically acceptable carrier,



---

in which

$\text{R}^2$ ,  $\text{R}^4$  denote H, A, Hal, cycloalkyl having 3 to 7 C atoms,  $\text{CF}_3$ ,  $\text{NO}_2$ , CN,  $\text{OCF}_3$ , OA, NHA,  $\text{NA}_2$ , or  $\text{NH}_2$ ,

$\text{R}^6$  is phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl,

















R<sup>3</sup> is phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl or 2- or 3-furanyl,















R<sup>1</sup> denotes H or CO<sub>2</sub>R<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>COHet, CHO, (CH<sub>2</sub>)<sub>n</sub>OR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)<sub>2</sub>, CH=N-OA, CH<sub>2</sub>CH=N-OA, (CH<sub>2</sub>)<sub>n</sub>NHOA, (CH<sub>2</sub>)<sub>n</sub>(R<sup>5</sup>)Het, (CH<sub>2</sub>)<sub>n</sub>CH=N-Het, (CH<sub>2</sub>)<sub>n</sub>OCOR', (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>OR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>OCF<sub>3</sub>, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)C(R<sup>5</sup>)OCOR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>(R')CH<sub>2</sub>COHet, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>N(R')CH<sub>2</sub>OCOR', (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>N(R<sup>5</sup>)<sub>2</sub>, CH=CHCOOR<sup>5</sup>, CH=CHCH<sub>2</sub>NR<sup>5</sup>Het, CH=CHCH<sub>2</sub>N(R<sup>5</sup>)<sub>2</sub>, CH=CHCH<sub>2</sub>OR<sup>5</sup> or (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)Ar,

R<sup>5</sup> denotes H or A















A denotes straight-chain or branched alkyl or alkoxy having 1 to 10 C atoms, or alkenyl or alkenyloxyalkyl having 2 to 10 C atoms,

Het is 1-piperidyl, 1-piperazyl, 1-(4-methyl)piperazyl, 1-(4-ethyl)piperazinyl, 1-(4-cyclopentyl)piperazinyl, 4-methylpiperazin-1-ylamine, 1-pyrrolidinyl, 1-pyrazolidinyl 1-(2-methyl)pyrazolidinyl, 1-imidazolidinyl or 1-(3-methyl)imidazolidinyl or 4-pyridyl, which is unsubstituted or substituted by one or more CN group, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl, or a group of one of the formulae below












 _____	 _____
 _____	 _____
 _____	 _____
 _____	 _____
 _____	 _____
 _____	 _____
 _____	 _____
 _____	 _____

 _____	 _____
 _____	 _____
 _____	 _____
 _____	 _____
 _____	 _____
 _____	 _____
 _____	 _____



 _____	 _____
 _____	 _____
 _____	 _____
 _____	 _____
 _____	 _____
 _____	 _____
 _____	 _____

 <chem>CN1CCCCC1=NOC</chem>	 <chem>CN1CCN(CCC1)c2ccc(C#N)cn2</chem>
 <chem>CN1CCCCC1Cc2ccccn2</chem>	 <chem>CN1C(=O)C=CC=C1</chem>
 <chem>CN1CCCCC1COC</chem>	 <chem>CN1CCCC1</chem>
 <chem>CN(C)CCNC</chem>	 <chem>CN1CCCC1COC</chem>
 <chem>CN1CC(O)CC1C(=O)OC</chem>	 <chem>CN1CCCC1=OSC</chem>
 <chem>CN1CCCC1CNc2c[nH]c3ccccc23</chem>	 <chem>CN1CCCC1C(=O)N(C)C</chem>
 <chem>CN(C)C1=NC2=C(N1)N=CN=C2C(C)C</chem>	 <chem>CN1CCCC1N</chem>

 _____	 _____
 _____	 _____
 _____	 _____
 _____	 _____
 _____	 _____ or _____
 _____	

Ar denotes a phenyl radical which is unsubstituted or mono or polysubstituted by  
A and/or Hal, OR<sup>5</sup>, OOCR<sup>5</sup>, COOR<sup>5</sup>, CON(R<sup>5</sup>)<sub>2</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, NHCOR<sup>5</sup>, CF<sub>3</sub> or



X denotes CH or N,

n denotes 0, 1, 2, 3, 4 or 5 and

Hal denotes F, Cl, Br or I,


where, in the case that X has the meaning CH, R<sup>2</sup> and R<sup>4</sup> do not simultaneously denote H,


or a salt, enantiomer, or racemate thereof, or a mixture of enantiomers.

15. (Currently Amended) A process for the preparation of a pharmaceutical composition, comprising combining a compound of the formula I according to Claim 14 [[+]] and/or one of its physiological acceptable salts into a suitable dosage form together with at least one solid, liquid or semi-liquid excipient or adjuvant.

16. (Cancelled)

17. (Currently Amended) A compound according to claim 28 [[+]], in which Het is





18. (Cancelled)

19. (Currently Amended) A method for the *in vitro* inhibition of 5-HT<sub>2A</sub> receptor, comprising administering to said receptor a pharmaceutical composition according to claim 14 compound, salt, enantiomer, racemate or enantiomer mixture of claim 1.

20. (Currently Amended) A compound according to claim 1, in which R<sup>1</sup> denotes ~~H or~~ (CH<sub>2</sub>)<sub>n</sub>COHet, CHO, (CH<sub>2</sub>)<sub>n</sub>OR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)<sub>2</sub>, CH=N-OA, CH<sub>2</sub>CH=N-OA, (CH<sub>2</sub>)<sub>n</sub>NHOA, (CH<sub>2</sub>)<sub>n</sub>(R<sup>5</sup>)Het, (CH<sub>2</sub>)<sub>n</sub>CH=N-Het, (CH<sub>2</sub>)<sub>n</sub>OCOR<sup>1</sup>, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>OR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>OCF<sub>3</sub>, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)C(R<sup>5</sup>)OCOR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>COHet, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>N(R<sup>5</sup>)CH<sub>2</sub>OCOR<sup>1</sup>, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>N(R<sup>5</sup>)<sub>2</sub>, CH=CHCOOR<sup>5</sup>, CH=CHCH<sub>2</sub>NR<sup>5</sup>Het, CH=CHCH<sub>2</sub>N(R<sup>5</sup>)<sub>2</sub>, CH=CHCH<sub>2</sub>OR<sup>5</sup> or (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)Ar.

21. (Currently Amended) A compound according to claim 1, in which R<sup>1</sup> denotes ~~H or~~ CO<sub>2</sub>R<sup>5</sup>, COHet, CHO, (CH<sub>2</sub>)<sub>n</sub>OR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)<sub>2</sub>, CH=N-OA, CH<sub>2</sub>CH=N-OA, (CH<sub>2</sub>)<sub>n</sub>NHOA, (CH<sub>2</sub>)<sub>n</sub>(R<sup>5</sup>)Het, (CH<sub>2</sub>)<sub>n</sub>CH=N-Het, (CH<sub>2</sub>)<sub>n</sub>OCOR<sup>1</sup>, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>OR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>OCF<sub>3</sub>, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)C(R<sup>5</sup>)OCOR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>COHet, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>N(R<sup>5</sup>)CH<sub>2</sub>OCOR<sup>1</sup>, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>N(R<sup>5</sup>)<sub>2</sub>, CH=CHCOOR<sup>5</sup>, CH=CHCH<sub>2</sub>NR<sup>5</sup>Het, CH=CHCH<sub>2</sub>N(R<sup>5</sup>)<sub>2</sub>, CH=CHCH<sub>2</sub>OR<sup>5</sup> or (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)Ar.

22. (Currently Amended) A compound according to claim 1, in which R<sup>1</sup> denotes ~~H or~~ (CH<sub>2</sub>)<sub>n</sub>Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)<sub>2</sub>, CH=N-OA, CH<sub>2</sub>CH=N-OA, (CH<sub>2</sub>)<sub>n</sub>NHOA,

$(\text{CH}_2)_n(\text{R}^5)\text{Het}$ ,  $(\text{CH}_2)_n\text{CH}=\text{N}-\text{Het}$ ,  $(\text{CH}_2)_n\text{OCOR}^1$ ,  $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{OR}^5$ ,  
 $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{OCF}_3$ ,  $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{C}(\text{R}^5)\text{OCOR}^5$ ,  $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{COHet}$ ,  
 $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{Het}$ ,  $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{Het}$ ,  $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{N}(\text{R}^1)\text{CH}_2\text{OCOR}^1$ ,  
 $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{N}(\text{R}^5)_2$ ,  $\text{CH}=\text{CHCOOR}^5$ ,  $\text{CH}=\text{CHCH}_2\text{NR}^5\text{Het}$ ,  $\text{CH}=\text{CHCH}_2\text{N}(\text{R}^5)_2$ ,  
 $\text{CH}=\text{CHCH}_2\text{OR}^5$  or  $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{Ar}$ .

23. (Previously Presented) A compound according to claim 1 or a pharmaceutically acceptable salt thereof.


24. (Previously Presented) A compound according to claim 1, in which  $\text{R}^3$  is thiophen-2-yl or thiophen-3-yl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl or 2- or 3-furanyl.

25. (Previously Presented) A compound according to claim 1, in which  $\text{R}^3$  is 2- or 3-furanyl.

26. (New) A compound according to claim 1, in which  $\text{R}^4$  denote A, Hal, cycloalkyl having 3 to 7 C atoms,  $\text{CF}_3$ ,  $\text{NO}_2$ , CN,  $\text{OCF}_3$ , OA, NHA,  $\text{NA}_2$ , or  $\text{NH}_2$ .

27. (New) A compound according to claim 1, in which A denotes straight-chain or branched alkyl or alkoxy having 3 to 10 C atoms, or alkenyl or alkenyloxyalkyl having 3 to 10 C atoms.

28. (New) A compound of formula I



in which

$R^2, R^4$  denote H, A, Hal, cycloalkyl having 3 to 7 C atoms,  $CF_3$ ,  $NO_2$ ,  $CN$ ,  $OCF_3$ ,  $OA$ ,  $NHA$ ,  $NA_2$ , or  $NH_2$ ,

$R^6$  is phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl,

$R^3$  is phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl or 2- or 3-furanyl,















$R^1$  denotes H or  $CO_2R^5$ ,  $(CH_2)_nCOHet$ ,  $CHO$ ,  $(CH_2)_nOR^5$ ,  $(CH_2)_nHet$ ,  $(CH_2)_nN(R^5)_2$ ,  $CH=N-OA$ ,  $CH_2CH=N-OA$ ,  $(CH_2)_nNHOA$ ,  $(CH_2)_n(R^5)Het$ ,  $(CH_2)_nCH=N-Het$ ,  $(CH_2)_nOCOR'$ ,  $(CH_2)_nN(R^5)CH_2CH_2OR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2OCF_3$ ,  $(CH_2)_nN(R^5)C(R^5)OCOR^5$ ,  $(CH_2)_nN(R')CH_2COHet$ ,  $(CH_2)_nN(R^5)CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R')CH_2OCOR'$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$ ,  $CH=CHCOOR^5$ ,  $CH=CHCH_2NR^5Het$ ,  $CH=CHCH_2N(R^5)_2$ ,  $CH=CHCH_2OR^5$  or  $(CH_2)_nN(R^5)Ar$ ,

$R^5$  denotes H or A















A denotes straight-chain or branched alkyl or alkoxy having 1 to 10 C atoms, or alkenyl or alkenyloxyalkyl having 2 to 10 C atoms,















Het is 1-piperidyl, 1-piperazyl, 1-(4-methyl)piperazyl, 1-(4-ethyl)piperazinyl, 1-(4-cyclopentyl)piperazinyl, 4-methylpiperazin-1-ylamine, 1-pyrrolidinyl, 1-pyrazolidinyl












1-(2-methyl)pyrazolidinyl, 1-imidazolidinyl or 1-(3-methyl)imidazolidinyl or 4-pyridyl, which is unsubstituted or substituted by one or more CN group, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl, or a group of one of the formulae below



Ar denotes a phenyl radical which is unsubstituted or mono or polysubstituted by A and/or Hal, OR<sup>5</sup>, OOCR<sup>5</sup>, COOR<sup>5</sup>, CON(R<sup>5</sup>)<sub>2</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, NHCOR<sup>5</sup>, CF<sub>3</sub> or SO<sub>2</sub>CH<sub>3</sub>,

X denotes CH or N,

n denotes 0, 1, 2, 3, 4 or 5 and

Hal denotes F, Cl, Br or I,

where, in the case that X has the meaning CH,  $R^2$  and  $R^4$  do not simultaneously denote H,

or a salt, enantiomer, or racemate thereof, or a mixture of enantiomers,

wherein at least one of the following three conditions I, II, or III is satisfied:

I)  $R^4$  denotes H, Hal, CN, A or  $NO_2$ ;

II)  $R^2$  denotes H or alkyl;

III) Het is

